The Food and Drug Administration has licensed the first freeze-dried plasma product for use in the United States, clearing a shelf-stable alternative to frozen plasma for adults who are bleeding in settings where conventional plasma cannot be stored or thawed.
The product, Ezplaz Freeze Dried Plasma, was licensed on July 29 to Vascular Solutions LLC, a subsidiary of Teleflex. It is indicated for transfusion in adult patients who need plasma and for whom other plasma products are not available. That includes patients who are bleeding, patients requiring massive transfusion, and certain patients experiencing bleeding while being treated with warfarin.
The FDA determined that for the approved uses, the benefits of Ezplaz transfusion outweigh the risks, and that its safety profile is consistent with other plasma products used for transfusion.
The Logistics Problem This Addresses
Plasma is the liquid fraction of blood that carries clotting factors, and it is a core component of resuscitation for patients losing large volumes of blood. The obstacle has never been whether it works. It has been where it can physically go.
Conventional fresh frozen plasma must be kept frozen, thawed before use, and is often packaged in glass. Each requirement assumes infrastructure: a freezer, a thawing device, a controlled transport chain. A rural ambulance two hours from a trauma center, a forward military unit or a clinic operating during a hurricane response typically has none of it.
Ezplaz is designed around the absence of that infrastructure. According to the FDA licensure announcement, the product can be stored at room temperature, remains stable after exposure to temperature fluctuations, and is rapidly reconstituted. It is packaged in a plastic bag rather than a glass bottle to reduce breakage during handling and transport.
"Patients experiencing life-threatening bleeding in combat zones, disasters, rural settings, or other austere environments may now have faster access to plasma when conventional frozen plasma is unavailable," said Karim Mikhail, acting director of the FDA's Center for Biologics Evaluation and Research. He described the action as addressing an important unmet medical need, particularly for military personnel and others far from traditional hospital infrastructure.
Manufacturing, Blood Type and Built-In Risk Mitigation
Ezplaz is a lyophilized plasma product derived from a single unit of fresh frozen plasma collected from FDA-licensed blood establishments. Freeze-drying removes the water while preserving the clotting proteins, and the powder is reconstituted at the point of use. Each kit is self-contained, holding one unit of freeze-dried plasma in a foil pouch, a 250 milliliter bag of sterile water for injection, a fluid transfer set, and a blood transfusion set. Prescribing details reported at licensure list a 12-month shelf life and reconstitution in roughly one to two and a half minutes.
The blood typing detail is a deliberate safety choice. The product is available in Group AB and in Group A with low-titer anti-B. Both were selected to reduce the risk of a transfusion reaction when the product is given in an emergency before a patient's blood type has been determined, which is the exact scenario the product exists to serve.
The AABB regulatory update noted that the manufacturer was required to develop its own Circular of Information for distribution with the product, and clinicians should review the full prescribing information before administration.
"This licensure demonstrates that innovation and rigorous scientific review can advance together, expanding treatment options and novel blood components while maintaining FDA's standards for safety, purity, and potency," said Anne Eder, director of the agency's Office of Blood Research and Review.
The Regulatory Path Began with a 2017 Law
Freeze dried plasma is not a new concept. It was used during World War II, withdrawn in the United States because pooled donor plasma carried hepatitis transmission risk, and has been in routine use by several allied militaries for years.
The route to full U.S. licensure ran through a specific statute. Freeze dried plasma was among the first products identified under Public Law 115-92, enacted in December 2017, which authorized a Defense Department and FDA collaboration to expedite development and review of products addressing serious or life-threatening conditions facing American military personnel. The FDA subsequently issued guidance on dried plasma products in 2019 to assist manufacturers.
Ezplaz is the first product from that pathway to reach U.S. licensure, which positions it as a reference point for other dried plasma products still in development.
Teleflex described the approval in its own announcement as its first biologics license for a blood component, and traced the work to a cooperative research agreement its Vascular Solutions subsidiary entered with a Defense Department medical program in 2014. Company statements about commercial significance are not independent evidence of clinical benefit, and the FDA's determination is the relevant regulatory finding.
Who Could Actually Benefit
Hemorrhage remains a leading cause of preventable death after traumatic injury, and the interval between injury and the first unit of plasma is one of the variables that changes outcomes.
People injured far from a trauma center are the clearest case. Rural residents in states with long transport times, and communities served by hospitals that have closed or reduced trauma capacity, face delays a room-temperature product could shorten. Patients requiring massive transfusion after severe trauma, obstetric hemorrhage or major surgery may benefit if the product allows earlier administration.
Patients bleeding while on warfarin are named specifically in the indication. Warfarin remains widely prescribed for atrial fibrillation and mechanical heart valves, particularly among older adults, and a bleeding event in that population is a medical emergency where reversal timing matters.
The indication is narrow in one respect that consumers should understand. Ezplaz is approved for adults, and for situations where other plasma products are not available. It is not a replacement for frozen plasma in a hospital that has frozen plasma.
From Licensure to Ambulances
Licensure is a regulatory event, not a distribution event. How quickly the product reaches ambulances, air medical services, rural hospitals, and military units depends on manufacturing scale-up, purchasing decisions by health systems and the Defense Department, and state emergency medical services protocols that govern what crews are permitted to carry and administer.
Those protocols vary by state. A patient in one state may see prehospital plasma years before a patient in another, and that gap will follow existing patterns in emergency care access.
Clinicians should consult the approved prescribing information directly before use. For families, there is no action to take. This is an infrastructure change in emergency medicine rather than a treatment anyone requests, and its value will be measured in transport times and survival data that take years to accumulate.
Frequently Asked Questions
What did the FDA approve? Ezplaz Freeze Dried Plasma, the first freeze-dried plasma product licensed for use in the United States, on July 29, 2026.
Who is it for? Adults who need plasma and for whom other plasma products are not available, including bleeding patients, patients requiring massive transfusion, and certain bleeding patients being treated with warfarin.
How is it different from regular plasma? Conventional plasma must be stored frozen, thawed before use, and is often in glass. Ezplaz is stored at room temperature, tolerates temperature swings, reconstitutes rapidly, and comes in a plastic bag.
Why does blood type matter here? The product comes in Group AB and Group A with low-titer anti-B, chosen to reduce reaction risk when it is given in emergencies before a patient's blood type is known.
Is this a new idea? No. Freeze-dried plasma has been used by several allied militaries for years and dates to World War II. This is the first full FDA licensure in the United States.
When will it be available in ambulances? That depends on manufacturing, purchasing decisions, and state emergency medical services protocols, which vary. Licensure does not automatically place a product on an ambulance.
Does this replace frozen plasma? No. The indication covers situations where other plasma products are not available, not routine hospital use where frozen plasma is on hand.
